Last reviewed · How we verify

Unita Complessa di Ostetricia e Ginecologia — Portfolio Competitive Intelligence Brief

Unita Complessa di Ostetricia e Ginecologia pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
testosterone undecanoate alone testosterone undecanoate alone phase 3 Androgen replacement therapy Androgen receptor Endocrinology
testosterone undecanoate plus letrozole testosterone undecanoate plus letrozole phase 3 aromatase inhibitor and androgen replacement therapy Gynecology
testosterone undecanoate plus dutasteride testosterone undecanoate plus dutasteride phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abbott · 1 shared drug class
  2. Acerus Pharmaceuticals Corporation · 1 shared drug class
  3. Acrux DDS Pty Ltd · 1 shared drug class
  4. Alliance for Clinical Trials in Oncology · 1 shared drug class
  5. Bayer · 1 shared drug class
  6. Beersheva Mental Health Center · 1 shared drug class
  7. Clarus Therapeutics, Inc. · 1 shared drug class
  8. Imperial College Healthcare NHS Trust · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Unita Complessa di Ostetricia e Ginecologia:

Cite this brief

Drug Landscape (2026). Unita Complessa di Ostetricia e Ginecologia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/unita-complessa-di-ostetricia-e-ginecologia. Accessed 2026-05-18.

Related